

Remarks

Claims 1-16, and 30-33 are pending in this application. Claims 7 and 9-14 were previously withdrawn as encompassing non-elected subject matter.

In the current Office Action, the Examiner requires restriction under 35 U.S.C. § 121 between the following groups of claims:

- Group 1** Claims 1-6, 15, 16, and 30-33, drawn to a method of treating a patient having an immunological disorder comprising administering an antibody that specifically binds to SEQ ID NO:1;
- Group 2** Claims 1-6, 8, 15, 16, and 30-33, drawn to a method of treating a patient having an immunological disorder comprising administering an antibody that specifically binds to SEQ ID NO:7; and
- Group 3** Claims 1-6, 8, 15, 16, and 30-33, drawn to a method of treating a patient having an immunological disorder comprising administering an antibody that specifically binds to SEQ ID NO:8.

Applicants elect Group 1 without traverse. Applicants have amended claims 1 and 30-32 accordingly.

Please grant any additional extensions of time required to enter this response
and charge any additional fees to deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: September 1, 2009

By: 

Nathaniel S. Edwards
Reg. No. 57,745
Tel.: 617.452.1669